Drug Profile
Research programme: diarrhoea therapies - Novartis/OneWorld Health
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Institute for OneWorld Health; Novartis
- Class
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diarrhoea
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Diarrhoea(In children) in USA
- 23 May 2012 Early research is ongoing in USA
- 15 Jul 2009 Early research in Diarrhoea in USA (unspecified route)